SAB Biotherapeutics (SABS) Competitors $2.23 +0.35 (+18.62%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.22 0.00 (-0.22%) As of 08/1/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SABS vs. ACHV, DOMH, FBIO, CRIS, BOLT, AMGN, GILD, VRTX, REGN, and ALNYShould you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Achieve Life Sciences (ACHV), Dominari (DOMH), Fortress Biotech (FBIO), Curis (CRIS), Bolt Biotherapeutics (BOLT), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Alnylam Pharmaceuticals (ALNY). These companies are all part of the "biotechnology" industry. SAB Biotherapeutics vs. Its Competitors Achieve Life Sciences Dominari Fortress Biotech Curis Bolt Biotherapeutics Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Achieve Life Sciences (NASDAQ:ACHV) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends. Do analysts recommend ACHV or SABS? Achieve Life Sciences presently has a consensus target price of $14.33, indicating a potential upside of 462.09%. SAB Biotherapeutics has a consensus target price of $13.00, indicating a potential upside of 482.96%. Given SAB Biotherapeutics' higher probable upside, analysts plainly believe SAB Biotherapeutics is more favorable than Achieve Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Achieve Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50SAB Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in ACHV or SABS? 33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 3.0% of Achieve Life Sciences shares are owned by insiders. Comparatively, 27.8% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is ACHV or SABS more profitable? SAB Biotherapeutics' return on equity of -105.14% beat Achieve Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Achieve Life SciencesN/A -176.11% -103.32% SAB Biotherapeutics N/A -105.14%-69.24% Which has more volatility and risk, ACHV or SABS? Achieve Life Sciences has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Does the media refer more to ACHV or SABS? In the previous week, Achieve Life Sciences had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 2 mentions for Achieve Life Sciences and 0 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.06 beat Achieve Life Sciences' score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Achieve Life Sciences Neutral SAB Biotherapeutics Positive Which has higher earnings and valuation, ACHV or SABS? SAB Biotherapeutics has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAchieve Life SciencesN/AN/A-$39.83M-$1.34-1.90SAB Biotherapeutics$1.32M15.69-$34.10M-$3.70-0.60 SummarySAB Biotherapeutics beats Achieve Life Sciences on 9 of the 15 factors compared between the two stocks. Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SABS vs. The Competition Export to ExcelMetricSAB BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.46M$3.00B$5.48B$9.52BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-0.6017.6228.6723.80Price / Sales15.69178.97373.5466.64Price / CashN/A41.9535.4557.96Price / Book0.798.508.275.55Net Income-$34.10M-$55.06M$3.24B$259.03M7 Day Performance-12.55%-3.98%-3.69%-4.59%1 Month Performance27.43%9.59%4.33%4.46%1 Year Performance-14.23%6.72%25.95%18.03% SAB Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SABSSAB Biotherapeutics3.4582 of 5 stars$2.23+18.6%$13.00+483.0%-19.5%$17.46M$1.32M-0.60140Positive NewsUpcoming EarningsACHVAchieve Life Sciences1.7746 of 5 stars$2.69+0.4%$14.33+432.8%-46.5%$92.96MN/A-2.0120Upcoming EarningsDOMHDominari0.6088 of 5 stars$5.25+2.7%N/A+157.9%$74.83M$18.15M-1.174Positive NewsUpcoming EarningsFBIOFortress Biotech2.4755 of 5 stars$1.98+0.5%$21.00+960.6%-13.4%$58.25M$57.67M-0.89170CRISCuris1.5272 of 5 stars$1.82-1.1%$17.00+834.1%-67.0%$19.25M$10.91M-0.2960Upcoming EarningsShort Interest ↑BOLTBolt Biotherapeutics1.9406 of 5 stars$6.30-0.3%$50.00+693.7%-62.4%$12.11M$7.69M-0.1990Gap DownAMGNAmgen4.5143 of 5 stars$301.29-1.7%$307.27+2.0%-11.5%$164.85B$33.42B27.4928,000Positive NewsUpcoming EarningsDividend AnnouncementGILDGilead Sciences4.6332 of 5 stars$113.03-2.7%$112.36-0.6%+48.0%$144.54B$28.75B23.8017,600Positive NewsUpcoming EarningsInsider TradeVRTXVertex Pharmaceuticals4.3406 of 5 stars$460.83-1.9%$512.30+11.2%-8.6%$120.60B$11.10B-117.566,100Positive NewsUpcoming EarningsShort Interest ↑High Trading VolumeREGNRegeneron Pharmaceuticals4.9128 of 5 stars$558.63-0.8%$828.86+48.4%-48.9%$60.80B$14.20B14.2215,106Trending NewsAnalyst ForecastGap UpALNYAlnylam Pharmaceuticals3.8859 of 5 stars$324.79-1.2%$347.75+7.1%+49.6%$42.87B$2.25B-155.402,230Trending NewsAnalyst Forecast Related Companies and Tools Related Companies ACHV Competitors DOMH Competitors FBIO Competitors CRIS Competitors BOLT Competitors AMGN Competitors GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SABS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
